Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 5270 participants.

Also called NCT07383155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,270 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07383155
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07383155. Randomized; no masking; primary purpose treatment. Start 2026-02-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Acronym
BRIGHT-HBR
Condition
High Bleeding Risk
Condition
Acute Coronary Syndromes
Condition
Anticoagulant Therapy
Intervention (Drug)
Anticoagulant Therapy
Lead sponsor
Shenyang Northern Hospital (class: other)

Record details

Record id
cardio:ct-nct07383155
Content hash
a43049f36a2021ed2ccdc25f6a1430124ad68761ca3190bb8c6b32a1ab753e17